The Incidence of Abemaciclib-induced Interstitial Lung Disease: A Single-center Retrospective Study in Japan
{{output}}
Background and aim: Abemaciclib, a CDK4/6 inhibitor, is used for estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Interstitial lung disease (ILD) is a frequent adverse event... ...
